Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature

Clin Genitourin Cancer. 2017 Oct;15(5):e885-e887. doi: 10.1016/j.clgc.2017.05.004. Epub 2017 May 10.

Authors

Pauline Bertolaso¹, Marine Gross-Goupil¹, Mathieu Molimard², Valérie Cochin³, Alain Ravaud³, Amaury Daste⁴

Affiliations

¹ Department of Medical Oncology, Hôpital Saint-André, University Hospital-CHU Bordeaux, France.
² Pharmacology Department, Université de Bordeaux INSERM U657, Bordeaux, France.
³ Department of Medical Oncology, Hôpital Saint-André, University Hospital-CHU Bordeaux, France; University of Bordeaux, Bordeaux, France.
⁴ Department of Medical Oncology, Hôpital Saint-André, University Hospital-CHU Bordeaux, France. Electronic address: [email protected].

PMID: 28552572
DOI: 10.1016/j.clgc.2017.05.004

No abstract available

Keywords: Metastatic renal cell carcinoma; Pharmacokinetics; TKI; Therapeutic drug monitoring; VEGF-R targeted therapy.

Publication types

Case Reports
Review

MeSH terms

Aged
Antineoplastic Agents / administration & dosage*
Antineoplastic Agents / pharmacokinetics
Carcinoma, Renal Cell / drug therapy*
Comorbidity
Drug Interactions
Drug Monitoring
Female
Humans
Indoles / administration & dosage*
Indoles / pharmacokinetics
Kidney Neoplasms / drug therapy*
Pyrroles / administration & dosage*
Pyrroles / pharmacokinetics
Sunitinib

Substances

Antineoplastic Agents
Indoles
Pyrroles
Sunitinib